Methylisothiazolinone: the epidemic is declining – but not gone

Urwin, Rachel; Craig, Sarah; Latheef, Faheem; Wilkinson, S. M.

doi:10.1111/cod.12750

Cited by 52 publications

(34 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, our population of MI‐sensitive patients was comparable to those in other documented series of cases of MI contact dermatitis, with patients being predominantly female and the hands and faces being most frequently involved . As previously reported, two thirds of the products implicated were cosmetics, followed by household products. Our series also confirmed the high share (11%) of water‐based paints as a cause of the condition, together with the involvement of cosmetic and household products containing MI in cases of domestic MI dermatitis .…”

Section: Discussionsupporting

confidence: 81%

Methylisothiazolinone allergic contact dermatitis: Assessment of relapses in 139 patients after avoidance advice

et al. 2019

View full text Add to dashboard Cite

Background Methylisothiazolinone (MI) is a preservative that is responsible for an epidemic of allergic contact dermatitis (ACD). Few studies have been published on the prognosis of patients with MI‐induced ACD. Objectives To evaluate relapses of MI‐induced ACD and difficulties in avoiding MI in patients who had received avoidance advice. Methods A retrospective study of patients with MI‐induced ACD diagnosed in two specialized dermato‐allergology units between 2010 and 2015 was performed. The median follow‐up was 3 years. Results Relapses were observed in 64% of 139 included patients, and were severe in 18%. Rinse‐off cosmetics were responsible for the largest proportion of relapses (27%). The median time to relapse was 5 months. Sixty‐nine per cent of relapses were on the hands, and 29% were on the face. Risk factors for relapsing were hand eczema and a personal history of atopy. The main difficulties encountered in the avoidance strategy were hidden sources of MI, the lack of labelling on industrial products, the complexity of cosmetic labelling, and remembering the name of the allergen. Conclusion MI‐induced ACD has a poor prognosis. Its high rate of relapse is mainly attributable to the difficulties of avoidance. Management needs to be improved. Specialized follow‐up in the year following diagnosis is essential to educate patients.

show abstract

Section: Discussionsupporting

confidence: 81%

Methylisothiazolinone allergic contact dermatitis: Assessment of relapses in 139 patients after avoidance advice

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In contrast, the prevalence of MI allergy in the United States was 10.9% in 2013 to 2014 . In Leeds, United Kingdom, MI allergy increased from ∼1% in 2009 to ∼10% in 2014, and decreased to 4% in 2015 . Data from 11 centres in Europe in 2015 showed proportions of 5% to 13% …”

Section: Discussionmentioning

confidence: 95%

The methylisothiazolinone contact allergy epidemic in Australia

2018

View full text Add to dashboard Cite

“…The incidence has markedly decreased since 2015, from a maximum of 18.9% in 2015 to 7.2% in 2018 and 3.1% in 2019. Urwin et al showed a decrease in the incidence of sensitization to MCI/MI or MI from 2013 to 2015 . Recently, Salman reviewed 324 patch‐tested patients between January 2016 and June 2018 in Istanbul, and observed a clear decrease in the prevalence of MCI/MI and/or MI sensitization from 10.15% in 2016, 9.25% in 2017, and 6.74% in 2018 .…”

Section: Discussionmentioning

confidence: 99%

Contact allergy to isothiazolinones epidemic: Current situation

et al. 2019

View full text Add to dashboard Cite

Background Since 2009, an increasing number of published cases of allergic contact dermatitis (ACD) from isothiazolinones in Europe was observed, amounting to an epidemic. However, only few studies have assessed the current situation after changes in European regulation. Objectives To analyze the incidence of isothiazolinone‐related ACD in our area in the last decade. Methods A retrospective study analyzed all patients patch tested in the allergy unit in a tertiary hospital in Spain between January 2010 and June 2019. Positive patch‐test reactions to methylchloroisothiazolinone (MCI)/methylisothiazolinone (MI) and/or MI alone were recorded. Results A total of 243 patients (9.55%) with positive patch‐test reactions to MCI/MI and/or MI alone among 2544 consecutively patch‐tested patients were recorded. An initial increase in the prevalence of MCI/MI allergy was observed, from 4.5% in 2010 reaching a peak in 2015, which was followed by a significant decrease until July 2019 with 3.1% prevalence in 2019. Conclusions As shown in our data, regulatory interventions have resulted in a dramatic decrease in the prevalence of MCI and MI ACD, reaching a pre‐epidemic level of 3.1% in 2019.

show abstract

Methylisothiazolinone: the epidemic is declining – but not gone

Cited by 52 publications

References 4 publications

Methylisothiazolinone allergic contact dermatitis: Assessment of relapses in 139 patients after avoidance advice

Methylisothiazolinone allergic contact dermatitis: Assessment of relapses in 139 patients after avoidance advice

The methylisothiazolinone contact allergy epidemic in Australia

Contact allergy to isothiazolinones epidemic: Current situation

Contact Info

Product

Resources

About